<p><strong>Renal Impairment:</strong>&nbsp;Dosage may need to be reduced.<br />
<br />
<strong>Hepatic Impairment:</strong></p>

<ul>
	<li><strong>Crohn&#39;s disease</strong>: Dosage may need to be reduced.</li>
	<li><strong>Acute lymphocytic leukemia</strong>: Dosage may need to be reduced</li>
</ul>

<p>Dosage adjustment in patients with thiopurine-S-methyl transferase (TPMT) deficiency to prevent life-threatening myelotoxicity.<br />
<br />
<strong>For patients with homozygous TPMT deficiency</strong>: Substantial reduction is required.<br />
<br />
<strong>For patients with heterozygous TPMT deficiency</strong>: Some may require reduction but most will tolerate the usual dosages.</p>